Evotec SE (EVO) Liabilities from Discontinued Operations (2024 - 2025)
Evotec SE (EVO) posted Liabilities from Discontinued Operations of 46863.91 for Q3 2025, up 474.87% sequentially from 8152.08 in Q3 2024, and up 474.87% YoY from 8152.08 in Q3 2024.
Evotec SE (EVO) Liabilities from Discontinued Operations (2024 - 2025) Analysis & Trends
Evotec SE has reported Liabilities from Discontinued Operations for 2 years, with the latest figure at 46863.91 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Evotec SE | 687.23 Mn | 686.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 46,863.91 |
| Sep 30, 2025 | 46,863.91 |
| Sep 30, 2024 | 8,152.08 |
| Sep 30, 2024 | 8,152.08 |